inflarx - Search News

InflaRx, EU

InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing authorization, under exceptional circumstances, for Gohibic (vilobelimab) to treat adult patients with acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2.

Business Insider · 11h

InflaRx’s Market Potential Bolstered by EU Approval of Gohibic

H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $8.00.Stay

Seeking Alpha on MSN · 1d

InflaRx gets EU okay for Gohibic for COVID-19 respiratory distress

InflaRx (NASDAQ:IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients experiencing acute respiratory distress. The European Commission granted marketing authorization under exceptional circumstances for Gohibic,

Hosted on MSN · 8h

InflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approval

H.C. Wainwright reaffirmed its Buy rating and $8.00 price target for InflaRx NV (NASDAQ:IFRX), following the European Commission's approval of the company's treatment for COVID-19 related complications.

Business Insider · 1d

InflaRx announces EC grants marketing authorization to Gohibic for ARDS

InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the

InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS

The European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic ...

Pharmaceutical Technology10d

INF-904 by InflaRx for Chronic Urticaria Or Hives: Likelihood of Approval

INF-904 is under clinical development by InflaRx and currently in Phase I for Chronic Urticaria Or Hives. According to GlobalData, Phase I drugs for Chronic Urticaria Or Hives have an 87% phase ...

CNN1y

InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR.

Yahoo Finance6d

InflaRx N.V. (IFRX)

JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

InflaRx, EU

Related topics